These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8593251)

  • 1. Phospholipid regulation of a cyclic AMP-specific phosphodiesterase (PDE4) from U937 cells.
    DiSanto ME; Glaser KB; Heaslip RJ
    Cell Signal; 1995 Nov; 7(8):827-35. PubMed ID: 8593251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of a cyclic nucleotide phosphodiesterase 4 (PDE4) from rat thymocytes by phosphatidic acid.
    Savany A; Abriat C; Némoz G; Lagarde M; Prigent AF
    Cell Signal; 1996 Nov; 8(7):511-6. PubMed ID: 9023016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rolipram inhibition of phosphodiesterase-4 activation.
    DiSanto ME; Heaslip RJ
    Eur J Pharmacol; 1995 Jul; 290(2):169-72. PubMed ID: 8575533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram.
    Michie AM; Lobban M; Müller T; Harnett MM; Houslay MD
    Cell Signal; 1996 Feb; 8(2):97-110. PubMed ID: 8730511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
    Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.
    Kelly JJ; Barnes PJ; Giembycz MA
    Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):425-36. PubMed ID: 8809029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salbutamol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. Implications for the therapeutic use of beta-adrenoceptor agonists.
    Torphy TJ; Zhou HL; Foley JJ; Sarau HM; Manning CD; Barnette MS
    J Biol Chem; 1995 Oct; 270(40):23598-604. PubMed ID: 7559525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity.
    Torphy TJ; Zhou HL; Cieslinski LB
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1195-205. PubMed ID: 1335058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases.
    Souness JE; Rao S
    Cell Signal; 1997; 9(3-4):227-36. PubMed ID: 9218122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
    Souness JE; Griffin M; Maslen C; Ebsworth K; Scott LC; Pollock K; Palfreyman MN; Karlsson JA
    Br J Pharmacol; 1996 Jun; 118(3):649-58. PubMed ID: 8762090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
    Eckly AE; Lugnier C
    Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2.
    Giembycz MA; Corrigan CJ; Seybold J; Newton R; Barnes PJ
    Br J Pharmacol; 1996 Aug; 118(8):1945-58. PubMed ID: 8864528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiplicity within cyclic nucleotide phosphodiesterases.
    Rybalkin SD; Beavo JA
    Biochem Soc Trans; 1996 Nov; 24(4):1005-9. PubMed ID: 8968501
    [No Abstract]   [Full Text] [Related]  

  • 14. Induction of cyclic AMP and cyclic GMP 3':5'-cyclic nucleotide phosphodiesterase activities in neuroblastoma lines under differentiating conditions.
    Giorgi M; Giordano D; Caniglia C; Biagioni S; Augusti-Tocco G
    Int J Dev Neurosci; 1997 Jun; 15(3):309-19. PubMed ID: 9253655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding.
    Barnette MS; Bartus JO; Burman M; Christensen SB; Cieslinski LB; Esser KM; Prabhakar US; Rush JA; Torphy TJ
    Biochem Pharmacol; 1996 Apr; 51(7):949-56. PubMed ID: 8651945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
    Jacobitz S; McLaughlin MM; Livi GP; Burman M; Torphy TJ
    Mol Pharmacol; 1996 Oct; 50(4):891-9. PubMed ID: 8863835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular targeting, interaction with Src homology 3 (SH3) domains and rolipram-detected conformational switches in cAMP-specific PDE4A phosphodiesterase.
    Houslay MD; Scotland G; Erdogan S; Huston E; Mackenzie S; McCallum JF; McPhee I; Pooley L; Rena G; Ross A; Beard M; Peder A; Begg F; Wilkinson I; Yarwood S; Ackerman C; Houslay ES; Hoffman R; Engels P; Sullivan M; Bolger G
    Biochem Soc Trans; 1997 May; 25(2):374-81. PubMed ID: 9191121
    [No Abstract]   [Full Text] [Related]  

  • 18. Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D.
    Wang P; Myers JG; Wu P; Cheewatrakoolpong B; Egan RW; Billah MM
    Biochem Biophys Res Commun; 1997 May; 234(2):320-4. PubMed ID: 9177268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ontogeny of rolipram-sensitive, low-K(m), cyclic AMP-specific phosphodiesterase in rat brain.
    Zhang K; Farooqui SM; O'Donnell JM
    Brain Res Dev Brain Res; 1999 Jan; 112(1):11-9. PubMed ID: 9974155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression.
    Essayan DM; Huang SK; Kagey-Sobotka A; Lichtenstein LM
    J Allergy Clin Immunol; 1997 Jan; 99(1 Pt 1):28-37. PubMed ID: 9003208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.